Table 2.
LSM difference in msSBP/DBP (intent-to-treat population)
| N |
msSBP |
msDBP |
|||
|---|---|---|---|---|---|
| LSM change (SEM) | Difference (95% CI) | LSM change (SEM) | Difference (95% CI) | ||
| From baseline to week 8 | |||||
| Aml/Val+HCTZ | 133 | −30.5 (1.1) | −6.1 (−8.6, −3.6) | −13.8 (0.7) | −5.5 (−7.1, −3.9) |
| Aml+HCTZ | 206 | −24.3 (0.9) | P < 0.0001 | −8.3 (0.6) | P < 0.0001 |
| From week 4 to week 8 | |||||
| Aml/Val+HCTZ | 133 | −6.9 (0.9) | −3.8 (−6.1, −1.5) | −3.5 (0.6) | −2.6 (−3.9, −1.1) |
| Aml+HCTZ | 206 | −3.1 (0.8) | P = 0.0012 | −1.0 (0.5) | P = 0.0004 |
Abbreviations: LSM, least squares mean; MSSBP, mean sitting systolic blood pressure; MSDBP, mean sitting diastolic blood pressure; Aml/Val+HCTZ, amlodipine/valsartan+hydrochlorothiazide; Aml+HCTZ, amlodipine+hydrocholorothiazide; SEM, standard error of mean.